| Company Name: |
WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd.
|
| Tel: |
17702719238 17702719238 |
| Email: |
sales@sun-shinechem.com |
| Products Intro: |
Product Name:aldoxorubicin hydrochloride
CAS:1361563-03-2
Purity:98% HPLC Package:50.0mg;100.0mg; 200.0mg;500mg;1g;5g; 10g
|
| Company Name: |
Cckinase, Inc.
|
| Tel: |
+1 (732)236-3202 |
| Email: |
sales@cckinase.com |
| Products Intro: |
Product Name:AldoxorubicinHCl
CAS:1361563-03-2
Purity:98% Package:100 mg; 500mg; 1g
|
| Company Name: |
Absin Bioscience Inc.
|
| Tel: |
021-38015121 18438616290 |
| Email: |
wulan@absin.cn |
| Products Intro: |
Product Name:Aldoxorubicin•HCl
CAS:1361563-03-2
Purity:>98% Package:100mg;50mg
|
AldoxorubicinHCl manufacturers
|
| | AldoxorubicinHCl Basic information |
| Product Name: | AldoxorubicinHCl | | Synonyms: | CS-1410;ALDOXORUBICIN HCL; CHEMBL2107827; 1361563-03-2; D10384;Aldoxorubicin•CHEMBL2107827;D10384;Aldoxorubicin hydrochloride, 10 mM in DMSO | | CAS: | 1361563-03-2 | | MF: | C37H43ClN4O13 | | MW: | 787.22 | | EINECS: | | | Product Categories: | | | Mol File: | 1361563-03-2.mol |  |
| | AldoxorubicinHCl Chemical Properties |
| | AldoxorubicinHCl Usage And Synthesis |
| Uses | Aldoxorubicin (INNO-206) hydrochloride is an albumin-binding proagent of Doxorubicin (DNA topoisomerase II inhibitor), which is released from albumin under acidic conditions. Aldoxorubicin hydrochloride (INNO-206) has potent antitumor activities in various cancer cell lines and in murine tumor models. | | in vivo | Aldoxorubicin hydrochloride (INNO-206) (10.8 mg/kg, i.v.) shows significantly smaller tumor volumes and IgG levels on days 28, and is well tolerated with 90% of mice surviving until the termination of the study in the mice bearing the LAGκ-1A tumor[1]. Aldoxorubicin hydrochloride (INNO-206) shows a good safety profile at doses up to 260 mg/mL doxorubicin equivalents, and is able to induce tumor regressions in breast cancer, small cell lung cancer and sarcoma in phase I study[2]. Aldoxorubicin hydrochloride (INNO-206) shows superior activity over doxorubicin in a murine renal cell carcinoma model and in breast carcinoma xenograft models[3]. | | References | [1] Walker L, et al. Cell penetrating peptides fused to a thermally targeted biopolymer drug carrier improve the delivery and antitumor efficacy of an acid-sensitive doxorubicin derivative. Int J Pharm. 2012 Oct 15;436(1-2):825-32. DOI:10.1016/j.ijpharm.2012.07.043
[2] Graeser R, et al. INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model. Invest New Drugs. 2010 F DOI:10.1007/s10637-008-9208-2
[3] Eric Sanchez, et al. Anti-Myeloma Effects of the Novel Anthracycline Derivative INNO-206. Clin Cancer Res.2012 18; 3856.
[4] Kratz, F. INNO-206 (DOXO-EMCH), an Albumin-Binding Prodrug of Doxorubicin Under Development for Phase II Studies. Current Bioactive Compounds, 2011, 7(1): 33-38(6) |
| | AldoxorubicinHCl Preparation Products And Raw materials |
|